127 related articles for article (PubMed ID: 17455665)
21. [Present data on influenza virus isolated from ducks and chickens, and influenza virus C. Anti-influenza drugs].
Fernández del Campo JA
An R Acad Nac Med (Madr); 2004; 121(2):305-30. PubMed ID: 15563121
[TBL] [Abstract][Full Text] [Related]
22. Mutations of neuraminidase implicated in neuraminidase inhibitors resistance.
Ferraris O; Lina B
J Clin Virol; 2008 Jan; 41(1):13-9. PubMed ID: 18055254
[TBL] [Abstract][Full Text] [Related]
23. A novel neuraminidase deletion mutation conferring resistance to oseltamivir in clinical influenza A/H3N2 virus.
Abed Y; Baz M; Boivin G
J Infect Dis; 2009 Jan; 199(2):180-3. PubMed ID: 19046066
[TBL] [Abstract][Full Text] [Related]
24. Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses.
Deyde VM; Okomo-Adhiambo M; Sheu TG; Wallis TR; Fry A; Dharan N; Klimov AI; Gubareva LV
Antiviral Res; 2009 Jan; 81(1):16-24. PubMed ID: 18835410
[TBL] [Abstract][Full Text] [Related]
25. Implications of antiviral resistance of influenza viruses.
Monto AS
Clin Infect Dis; 2009 Feb; 48(4):397-9. PubMed ID: 19586376
[No Abstract] [Full Text] [Related]
26. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors.
Gubareva LV
Virus Res; 2004 Jul; 103(1-2):199-203. PubMed ID: 15163510
[TBL] [Abstract][Full Text] [Related]
27. Neuraminidase-inhibitor resistance testing for pandemic influenza A (H1N1) 2009 in Ontario, Canada.
Longtin J; Patel S; Eshaghi A; Lombos E; Higgins R; Alexander D; Olsha R; Doyle J; Tran D; Sarabia A; Lee C; Bastien N; Li Y; Low D; Boivin G; Gubbay J
J Clin Virol; 2011 Mar; 50(3):257-61. PubMed ID: 21251873
[TBL] [Abstract][Full Text] [Related]
28. Increased adamantane resistance in influenza A(H3) viruses in Australia and neighbouring countries in 2005.
Barr IG; Hurt AC; Iannello P; Tomasov C; Deed N; Komadina N
Antiviral Res; 2007 Feb; 73(2):112-7. PubMed ID: 16963130
[TBL] [Abstract][Full Text] [Related]
29. The medicinal potential of natural products for the development of anti- influenza agents.
Sun F; Huang R
Curr Drug Targets; 2014 Feb; 15(2):175-83. PubMed ID: 23962234
[TBL] [Abstract][Full Text] [Related]
30. Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses.
Hayden F; Klimov A; Tashiro M; Hay A; Monto A; McKimm-Breschkin J; Macken C; Hampson A; Webster RG; Amyard M; Zambon M
Antivir Ther; 2005; 10(8):873-7. PubMed ID: 16430192
[TBL] [Abstract][Full Text] [Related]
31. Emergence and phylogenetic relationships of amantadine-resistant human H3N2 influenza A viruses in Germany in the season 2005/2006.
Schmidtke M; Bauer K; Ludwig N; Wutzler P
Int J Antimicrob Agents; 2008 Aug; 32(2):192-5. PubMed ID: 18571381
[No Abstract] [Full Text] [Related]
32. Emergence of H274Y oseltamivir-resistant A(H1N1) influenza viruses in Japan during the 2008-2009 season.
Baranovich T; Saito R; Suzuki Y; Zaraket H; Dapat C; Caperig-Dapat I; Oguma T; Shabana II; Saito T; Suzuki H;
J Clin Virol; 2010 Jan; 47(1):23-8. PubMed ID: 19962344
[TBL] [Abstract][Full Text] [Related]
33. Drug resistance among influenza A viruses isolated in Italy from 2000 to 2005: are the emergence of Adamantane-resistant viruses cause of concern?
Ansaldi F; Valle L; Amicizia D; Banfi F; Pastorino B; Sticchi L; Icardi G; Gasparini R; Crovari P
J Prev Med Hyg; 2006 Mar; 47(1):1-3. PubMed ID: 17061402
[No Abstract] [Full Text] [Related]
34. High prevalence of amantadine-resistance influenza a (H3N2) in six prefectures, Japan, in the 2005-2006 season.
Saito R; Li D; Suzuki Y; Sato I; Masaki H; Nishimura H; Kawashima T; Shirahige Y; Shimomura C; Asoh N; Degawa S; Ishikawa H; Sato M; Shobugawa Y; Suzuki H
J Med Virol; 2007 Oct; 79(10):1569-76. PubMed ID: 17705168
[TBL] [Abstract][Full Text] [Related]
35. [M2 inhibitors and neuraminidase inhibitors].
Klebe G; Schlitzer M
Pharm Unserer Zeit; 2011 Mar; 40(2):144-50. PubMed ID: 21630541
[No Abstract] [Full Text] [Related]
36. Evolution of drug resistance in multiple distinct lineages of H5N1 avian influenza.
Hill AW; Guralnick RP; Wilson MJ; Habib F; Janies D
Infect Genet Evol; 2009 Mar; 9(2):169-78. PubMed ID: 19022400
[TBL] [Abstract][Full Text] [Related]
37. First isolation of a oseltamivir-resistant influenza A (H1N1) strain in Argentina.
Cané A; Casanueva E; Iolster T; Sticco N; Richards L; Sosa P; Pontoriero A; Avaro M; Zcech A; Carabajal E; Campos A; Baumeister E; Diez MA; Rojas M; Rivarola MR
Pediatr Infect Dis J; 2010 Apr; 29(4):384. PubMed ID: 20351531
[No Abstract] [Full Text] [Related]
38. Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors.
Hurt AC; Ho HT; Barr I
Expert Rev Anti Infect Ther; 2006 Oct; 4(5):795-805. PubMed ID: 17140356
[TBL] [Abstract][Full Text] [Related]
39. Adamantane resistance in influenza A(H1) viruses increased in 2007 in South East Asia but decreased in Australia and some other countries.
Barr IG; Deng YM; Iannello P; Hurt AC; Komadina N
Antiviral Res; 2008 Nov; 80(2):200-5. PubMed ID: 18611414
[TBL] [Abstract][Full Text] [Related]
40. Influenza virus susceptibility and resistance to oseltamivir.
Aoki FY; Boivin G; Roberts N
Antivir Ther; 2007; 12(4 Pt B):603-16. PubMed ID: 17944268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
